CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CAN-3110 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAN-3110 overview
CAN-3110 is under development for the treatment of recurrent malignant glioma, recurrent glioblastoma, anaplastic astrocytoma, oligodendroglioma, melanoma and high grade glioma. It is administered by intratumoral route. The drug candidate is an oncolytic virus, the human nestin promoter enhancer element to drive expression of the HSV1 gene, Y134.5, encoding the viral protein ICP34.5.It is based on enLIGHTEN discovery platform.
Candel Therapeutics overview
Candel Therapeutics is a clinical stage biopharmaceutical company. It manufactures, develops and tests cancer immunotherapy drugs and gene-based biologics. The company lead products candidate includes CAN-2409 and CAN-3110 for the treatment of non-small cell lung cancer (NSCLC), advanced non-metastatic pancreatic adenocarcinoma, prostate cancer, pancreatic cancer and recurrent high-grade glioma (rHGG). Candel Therapeutics also utilizes its Candel’s enlighten a systematic, HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.
For a complete picture of CAN-3110’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
